Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study of Multivirus-specific T Cells in the Treatment of Refractory Cytomegalovirus and/or Epstein-Barr Virus Infection After Allogeneic Hematopoietic Stem Cell Transplantation

NCT06075927 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT06075927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study of Multivirus-specific T Cells in the Treatment of Refractory Cytomegalovirus and/or Epstein-Barr Virus Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Peking University People's Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 1, 2023
Completion date
October 30, 2025
Enrollment
29 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cmv infection, ebv infection, stem cell transplant